EPO Patent Publication EP4630448A1 - Binding Molecule

The European Patent Office has published patent application EP4630448A1 concerning a binding molecule developed by Strike Pharma AB. The publication date is March 18, 2026, and it includes various International Patent Classifications related to pharmaceuticals and medical treatments.

EPO Patent Publication EP4630453A1: GP130 Antigen-Binding Molecules

The European Patent Office (EPO) published patent application EP4630453A1 on March 18, 2026, concerning GP130 antigen-binding molecules. The applicant is VVB Bio Pte. Ltd. This publication represents a new patent filing and does not impose new regulatory obligations.

EPO Patent EP4549563A1: Hyaluronidase Hyal1 Variant Active in Neutral pH

The European Patent Office has published patent application EP4549563A1 concerning a hyaluronidase Hyal1 variant that exhibits activity in neutral pH. The patent application was filed by Odysgen Inc. and lists Choi Mal-Gi and Lee Chang Woo as inventors.

EPO Patent EP4629960A1 Published: Aerosol Device

The European Patent Office (EPO) has published patent application EP4629960A1 concerning an aerosol device based on an anionic fixing polymer, direct dye, monoalcohol, and dimethyl ether. The patent was published on March 18, 2026, with L'Oreal listed as the applicant.

Unilever Patent EP4630124A1 for Transparent Liquid Cleansing Composition

The European Patent Office has published patent application EP4630124A1 for a transparent liquid cleansing composition, filed by Unilever IP Holdings B.V. and Unilever Global IP Limited. The patent details specific formulations and classifications related to cosmetic and detergent products.

EPO Patent Publication: Recombinant Fusion Protein Targeting PD-L1 and VEGF

The European Patent Office has published patent application EP4534564A1 concerning a recombinant fusion protein that targets PD-L1 and VEGF. The patent application was filed by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. and lists multiple inventors.

EPO Patent Publication EP4629991A1: Delayed Release Composition

The European Patent Office (EPO) published patent application EP4629991A1 on March 18, 2026, detailing a delayed release composition with resistance against fed-state gastric conditions. The applicant is Evonik Operations GmbH.

Amgen Heterocyclic Inhibitors for KRAS G12C Mutant Proteins

The European Patent Office has published patent application EP4598917A1 by Amgen Inc. detailing heterocyclic inhibitors for KRAS G12C mutant proteins. This publication relates to potential new therapeutic agents for cancer treatment.

Cancer Therapy Patent Application - Capivasertib and Fulvestrant

The European Patent Office has published a patent application (EP4630002A1) for a cancer therapy involving Capivasertib and Fulvestrant, with AstraZeneca AB listed as the applicant. The patent covers specific therapeutic uses and classifications related to oncology treatments.

EPO Patent EP4630013A1: T Cell Complex Identification and Isolation

The European Patent Office has published patent application EP4630013A1 concerning the identification and isolation of T cell-comprising cell-cell complexes and their use. The patent was filed by Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis and lists Daniel Simon Peeper, Sofía Ibáñez Molero, and Johanna Veldman as inventors.